Celltrion Pharm, Inc. (068760) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Celltrion Pharm, Inc. (068760:KRX), powered by AI.
- Current Price
- ₩44,050
- P/E Ratio
- 50.5
- Market Cap
- 2.0T
- Sector
- Healthcare
What is the Celltrion Pharm, Inc. stock price forecast?
Celltrion Pharm, Inc. is currently trading at ₩44,050. View real-time AI analysis on Alpha Lenz.
What is Celltrion Pharm, Inc. insider trading activity?
View the latest insider trading data for Celltrion Pharm, Inc. on Alpha Lenz.
What is Celltrion Pharm, Inc.'s P/E ratio?
Celltrion Pharm, Inc.'s P/E ratio is 50.5.
Celltrion Pharm, Inc.
KRX · 068760“Celltrion Pharm, Inc. trades at a P/E of 50.5 (premium valuation) with solid ROE of 9.3%. 3Y revenue CAGR of 11.6% highlights clear growth momentum.”
Ask for details →Company Overview
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Celltrion Pharm, Inc. trades at a P/E of 50.5 (premium valuation) with solid ROE of 9.3%. 3Y revenue CAGR of 11.6% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Celltrion Pharm, Inc. (ticker: 068760) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $2.0T.
The current price is ₩44,050 with a P/E ratio of 50.47x and P/B of 4.49x.
ROE is 9.31% and operating margin is 10.46%. Annual revenue is $536.4B.